Navigation Links
Multi Merci Trial Results Published in Peer Reviewed Journal
Date:3/6/2008

MOUNTAIN VIEW, Calif., March 6 /PRNewswire/ -- Concentric Medical, Inc., the global leader in devices for clot removal in ischemic stroke patients, today announced that the results of its Multi MERCI trial will be published in the April 2008 edition of the medical journal, Stroke. The Multi MERCI trial was the second trial studying safety and efficacy of the Merci Retrieval System(TM), a "corkscrew-type" device that is delivered into the brain and is designed to restore blood flow by engaging, capturing and removing blood clots that cause ischemic stroke. The full, peer reviewed trial results are available now to online subscribers. Stroke is published by the American Heart Association.

In the Multi MERCI trial, patients treated with the newer Merci(R) L5 Retriever had their cerebral blood flow successfully restored 57.3% of the time with the Merci Retrieval System alone. With the addition of adjunctive therapy, physicians successfully restored cerebral blood flow 69.5% of the time. For patients to be successfully revascularized, not only the target vessel, but all treatable downstream vessels needed to achieve TIMI 2 or 3 flow.

In addition, a total of 36% of all patients treated achieved a "good" outcome at 90 days post procedure, a higher rate than reported in any other device trial in large vessel acute ischemic stroke patients. Ninety-day clinical outcomes in stroke trials are generally measured using the modified Rankin Score, a measure of functional independence, with a score of 2 or less considered a good outcome. These outcome data are superior to those reported in recent studies of other devices in which successful revascularization was not as stringently defined.

Multi MERCI was a multi-center, prospective trial including 164 patients treated at 15 hospitals in the United States and Canada. All patients had moderate-to-severe, large vessel ischemic strokes. The trial included patients who were ineligible for or had failed treatm
'/>"/>

SOURCE Concentric Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
2. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
3. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
4. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
5. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
6. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
7. Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
8. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
9. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... MADRID , June 2, 2015 /PRNewswire/ ...   10503), vorgestellt auf dem Jahrestreffen der ... PharmaMar teilt mit, dass Janssen Research ... multizentrischen Phase-3-Studie SAR3007 bekannt gegeben hat, ... (progression-free survival, PFS) mit Trabectedin (YONDELIS ® ...
(Date:6/1/2015)... 2, 2015 Amgen (NASDAQ: AMGN ... a Phase 1b study to evaluate the safety ... immunotherapy, in combination with Roche,s investigational anti-PDL1 therapy, ... triple-negative breast cancer and colorectal cancer with liver ... oncolytic immunotherapy designed to selectively replicate in tumors ...
(Date:6/1/2015)... June 1, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular ... highlights and financial results for the three months ... herein are in Canadian dollars unless otherwise stated. ... business strategies despite its limited financial resources," stated ...
Breaking Medicine Technology:PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 2PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 3PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 4PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 5PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 2Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 3Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 4Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 5Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 7Pivotal Therapeutics Announces First Quarter Financial Results 2Pivotal Therapeutics Announces First Quarter Financial Results 3Pivotal Therapeutics Announces First Quarter Financial Results 4Pivotal Therapeutics Announces First Quarter Financial Results 5
... (Nasdaq: GNTA ) today announced financial results and progress,for ... noted,significant recent milestones, including:, -- ... -- New oral product, G4544, completes initial Phase ... -- Tesetaxel, a leading oral taxane, becomes new ...
... Committee Recommends FDA Approve Novel Anesthesia Drug to Reverse Muscle ... ... Schering-Plough,(NYSE: SGP ) today announced that the U.S. ... Support has recommended,sugammadex for approval. After reviewing data on the ...
Cached Medicine Technology:Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 2Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 3Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 4Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 5Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 6Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 7Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 8Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 9Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 10FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent 2FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent 3FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent 4
(Date:6/2/2015)... (PRWEB) June 02, 2015 Each year, ... Insiders’ Choice Beauty Awards. This year, the organization’s members ... the winner of the QVC® Beauty Quest Award at ... results-driven Micro Emulsion (ME) Technology and 2-in-1 approach to ... Also noting the brand’s loyal consumer and professional fan ...
(Date:6/2/2015)... 2015 SB 277 (CA Legislature, bit.ly/1Q0P8OY) ... to attend public or private school. SB277 cleared three ... the Appropriations Committee (Sacramento Bee, May 11, 2015, bit.ly/1Gh9jU7). ... , “We believe that this bill affects the ... than it will (the) affect public health of California.. ...
(Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... Miriam Wirski as a 2015-2016 inductee into ... recognized with this prestigious distinction for leadership in business. ... professional women, boasting more than 700,000 members and over ... Miriam with this prestigious honor,” said NAPW President Star ...
(Date:6/1/2015)... June 02, 2015 The National ... Willey as a 2015-2016 inductee into its VIP ... with this prestigious distinction for leadership in safety, environment, ... networking organization exclusively for professional women, boasting more than ... "I’m pleased to present Lourinda with this important honor,” ...
(Date:6/1/2015)... The National Association of Professional Women ... (C), First Sergeant A Co., 15BSB , as a ... Circle. She is recognized with this prestigious distinction for ... networking organization exclusively for professional women, boasting more than ... “I'm pleased to recognize Sergeant Cornett with this important ...
Breaking Medicine News(10 mins):Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lenita F. Cornett, First Sergeant of the US Military, Into its VIP Professional Woman of the Year Circle 2
... RIVERSIDE, California and NUREMBERG, Germany, June ... United States Food and Drug,Administration (FDA) has given 510k ... the Ziehm Vision(R) RFD, for marketing and,sales within the ... and interventional radiology, the Ziehm Vision RFD,mobile C-arm combines ...
... M.A.Z.E. ... is dedicated to helping parents save money and the giveaway is another chance for parents ... ... education with M.A.Z.E. Cord Blood Laboratories. M.A.Z.E. is offering a drawing to win a ...
... LONDON, June 10 ThirdForce, the UK,s leading,e-learning ... one of,the most respected care home companies in the UK, ... for Life,e-learning to enhance Barchester,s quality provision of care and ... a key component to the success of the,Barchester business; a ...
... percent of the 5.5 billion kilograms of toxic pollutant ... can be traced to just 30 substances from 15 ... according to the latest tri-national pollution report from the ... 2005, released today,represents the most complete picture of pollution ...
... difference to Ontario,s community mental health system? According to ... the answer is yes. Ontarians now have access to ... also highlights the system,s limited resources to serve all ... for Addiction and Mental Health (CAMH),s Dr. Paula Goering, ...
... New Tissue Dissection System Used by Italian Surgeons in Oncology ... PALO ALTO, Calif., June 10 PEAK Surgical, Inc., today ... surgeons in the European Union, where the innovative tissue dissection ... , Dr. Raul Pellini and Prof. Giuseppe Spriano, ear, nose ...
Cached Medicine News:Health News:SVS 2009: Ziehm Imaging Sets a New Standard in Mobile Imaging With the Ziehm Vision RFD 2Health News:SVS 2009: Ziehm Imaging Sets a New Standard in Mobile Imaging With the Ziehm Vision RFD 3Health News:M.A.Z.E. Cord Blood Laboratories Offers Expectant Parents The Chance To Win A $500 Savings Bond 2Health News:Barchester Healthcare Gains Skills for Life With ThirdForce 2Health News:Barchester Healthcare Gains Skills for Life With ThirdForce 3Health News:Latest trinational report presents most complete picture of North American industrial pollution 2Health News:Latest trinational report presents most complete picture of North American industrial pollution 3Health News:Evaluation shows $167 million investment improves community mental health system, but many still in need 2Health News:PEAK Surgical Announces First Use of PEAK PlasmaBlade(TM) in Europe 2Health News:PEAK Surgical Announces First Use of PEAK PlasmaBlade(TM) in Europe 3Health News:PEAK Surgical Announces First Use of PEAK PlasmaBlade(TM) in Europe 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: